Effect of a Histone Deacetylases Inhibitor of IL-18 and TNF-Alpha Secretion in Vitro
DOI:
https://doi.org/10.3889/oamjms.2018.075Keywords:
HDAC, IL-18, SAHA, TNF-α, PBMCAbstract
BACKGROUND: Interleukin-18 (IL-18) and Tumor Necrosis Factor-alpha (TNF-α) are proinflammatory cytokines that increased the development of Th1 immune response, but have a different type of regulation of the gene expression. Whereas TNF-α has an inducible expression, IL-18 is translated as an inactive protein and required proteolytic cleavage by Casp-1 in inflammasome complexes.
AIM: To investigate the effect of the histone deacetylases inhibitor Suberoylanilide Hydroxamic Acid (SAHA) on the gene expression and secretion of both cytokines, IL-18 and TNF-α, according to their contribution to the cancer development and anticancer immunity.
METHODS: Isolated peripheral blood mononuclear cells (PBMC) were stimulated with LPS and C3bgp with or without SAHA. Cytokine production was assessed by ELISA at 6 and 24h.
RESULTS: IL-18 and TNF-α secretion was significantly increased at 6h and 24h in response to stimulation. TNF-α production from stimulated PBMC was downregulated by SAHA at 6 and 24h. Treatment with SAHA does not inhibit the secretion of IL-18 significantly either at 6 or 24h of stimulation.
CONCLUSION: The inhibition of histone deacetylases by SAHA does not influence the inflammasome-dependent production of immunologically active IL-18. In contrast, the production of proinflammatory TNF-α in cultures was mediated by the activity of HDAC class I and class II enzymes.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Li N, Zhao D, Kirschbaum M, Zhang C, Lin CL, Todorov I, Kandeel F, Forman S, and Zeng D. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. PNAS. 2008; 105:4796-4801. https://doi.org/10.1073/pnas.0712051105 PMid:18347343 PMCid:PMC2290749
Roger T, Lugrin J, Le Roi D, Goy G, Mombelli M, Koessier T, Ding XC, Chanson AL, Reymond MK, Miconnet I, Schrenzel J, Francois P, and Calandra T. Histone deacetylase inhibitors impair innate immune response to Toll-like receptor agonist and to infection. Blood. 2011; 117:1205-1217. https://doi.org/10.1182/blood-2010-05-284711 PMid:20956800
Shakespear MR, Halili MA, Irvine KM, Fairlie DP, and Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends in Immunology. 2011; 32:335-343. https://doi.org/10.1016/j.it.2011.04.001 PMid:21570914
Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, Lovelace E, Reid RC, Le GT, Hume D, Irvine KM, Matthias P, Fairlie DP, and Sweet MJ. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leuk Biol. 2010; 87:1-11. https://doi.org/10.1189/jlb.0509363 PMid:20200406
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5:769–784. https://doi.org/10.1038/nrd2133 PMid:16955068
Wang Z, Chen C, Finger SN, Kwajah SMM, Jung M, Schwarz H, Swanson N, Lareu RR, and Raghunath M. Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Eur Respir J. 2009; 34:145–155. https://doi.org/10.1183/09031936.00084808 PMid:19224893
Tiffon CE, Adams JE, Fits van der L, Wen S, Townsend PA, Ganesan A, Hodges E, Vermeer MH, and Packham G. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol. 2011; 162:1590–1602. https://doi.org/10.1111/j.1476-5381.2010.01188.x PMid:21198545 PMCid:PMC3057296
Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics: Targets and Therapy. 2013; 7:47–60. PMid:23459471 PMCid:PMC3584656
Wu Y and Zhou BP. TNF-a/NF-kB/Snail pathway in cancer cell migration and invasion. British Journal of Cancer. 2010; 102:639 – 644. https://doi.org/10.1038/sj.bjc.6605530 PMid:20087353 PMCid:PMC2837572
Bell JH, Herrera AH, Li Y, Walcheck B. Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J Leukoc Biol. 2007; 82:173–176. https://doi.org/10.1189/jlb.0307193 PMid:17510296
Fabbi M, Carbotti G, and Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leuk Biol. 2015; 97:665-675. https://doi.org/10.1189/jlb.5RU0714-360RR PMid:25548255
Dinarello CA. IL-18: A TH1 -inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999; 103:11-24. https://doi.org/10.1016/S0091-6749(99)70518-X
Dobreva ZG, Grigorov BG, Stanilova SA. Suppression of IL-12p40-related regulatory cytokines by suberoylanilide hydroxamic acid an inhibitor of histone deacetylases. Immunopharmacol Immunotoxicol. 2016; 38:281-285. https://doi.org/10.1080/08923973.2016.1188940 PMid:27240992
Zhelev Z, Stanilova S, Carpenter B. Isolation, partial characterization and complement inhibiting activity of a new glycoprotein from Cuscuta europea. Biochem Biophys Res Commun. 1994; 202:86–94. https://doi.org/10.1006/bbrc.1994.1911
Balkwill F. Tumour necrosis factor and cancer. Nature Reviews Cancer. 2009; 9:361-371. https://doi.org/10.1038/nrc2628 PMid:19343034
Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, and Mascagni P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. PNAS. 2002; 99:2995-3000. https://doi.org/10.1073/pnas.052702999 PMid:11867742 PMCid:PMC122461
Takada Y, Gillenwater A, Ichikawa H, and Aggarwa BB. Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-kB Activation. J Biol Chem. 2006; 281:5612–5622. https://doi.org/10.1074/jbc.M507213200 PMid:16377638
Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ, and Dalpke HA. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology. 2007; 122:596–606. https://doi.org/10.1111/j.1365-2567.2007.02678.x PMid:17635610 PMCid:PMC2266046
Dobreva ZG, Stanilova SA. The immunomodulatory activity of C3 binding glycoprotein (C3bgp) is mediated by the complement receptor type III and mitogen-activated protein kinase signal transduction pathways. Immunopharmacol & Immunotoxicol. 2007; 29:549-562. https://doi.org/10.1080/08923970701691017 PMid:18075864
Ajizian SJ, English BK, Meals EA. Specific Inhibitors of p38 and Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Pathways Block Inducible Nitric Oxide Synthase and Tumor Necrosis Factor Accumulation in Murine Macrophages Stimulated with Lipopolysaccharide and Interferon-γ. J Infect Dis. 1999; 179:939–44. https://doi.org/10.1086/314659 PMid:10068590
Choo QY, Ho PC, Tanaka Y, and Lin HS. The histone deacetylase inhibitors MS-275 and SAHA suppress the p38 mitogen-activated protein kinase signaling pathway and chemotaxis in rheumatoid arthritis synovial fibroblastic E11 cells. Molecules. 2013; 18:14085-14095. https://doi.org/10.3390/molecules181114085 PMid:24241152
Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT, and Tahara H. IFN-g-inducing factor/IL-18 Administration Mediates IFN-g-and IL-12-Independent Antitumor Effects. J Immunol. 1998; 160:1742-1749. PMid:9469432
Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, Carrascal T, Walsh P, Reznikov LL, Kim SH, Novick D, Rubinstein M, and Dinarello CA. IL-18 regulates IL-1ï¢-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. PNAS. 2000; 97:734-739. https://doi.org/10.1073/pnas.97.2.734 PMid:10639148 PMCid:PMC15399
Fernandes JV, Cobucci RNO. Jatobá CAN. Fernandes TAAM, Azevedo JWV, Araújo JMG. The Role of the Mediators of Inflammation in Cancer Development. Pathol Oncol Res. 2015; 21:527-534. https://doi.org/10.1007/s12253-015-9913-z PMid:25740073
Lissoni P, Brivio F, Rovelli F, Fumagalli G, Malugani F, Vaghi M, Secondino S, Bucovec R, Gardani GS. Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents. 2000; 14:275-277. PMid:11215816
Choo QY, Ho PC, Tanaka Y, and Lin HS. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology. 2010; 49:1447–1460. https://doi.org/10.1093/rheumatology/keq108 PMid:20421217
Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW. Gene Expression Profiles in Normal and Cancer Cells. Science. 1997; 276:1268-1272. https://doi.org/10.1126/science.276.5316.1268 PMid:9157888
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454:436-444. https://doi.org/10.1038/nature07205 PMid:18650914
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
